All in all, Ingrezza pulled in $2.3 billion in 2024, making for an “all-time record growth year” for the drug, Benevich noted. Teva's Austedo, meanwhile, collected $1.6 billion in sales last year.

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Does Warren Buffett Know Something That Wall Street Doesn't? The Billionaire Investor Is Piling Into a High-Yield Stock That Certain Analysts Recommend Selling. Mark Cuban's $400K Bet On Teen ...

Agnico Eagle Mines Expects Gold Production Forecast To Remain Stable At 3.30 - 3.50 Million Ounces Annually In 2025 To 2027, Consistent With 2024, And 3% Lower Than Prior Guidance In Years 2025 ...

Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...

Found the MG ZS of your dreams? Now you want to know all about it! With the help of Parkers, you can find out all of the key specs about the MG ZS from fuel efficiency in MPG and top speed in MPH, to ...